When treatment-naïve EGFR-mutated NSCLC was treated with TKIs, the initial treatment response was accompanied by an increase in cytotoxic CD8+ T cell infiltration but a reduction in immunosuppressive Tregs and M2-like TAMs [6,73,74]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.